A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation - Trial NCT06312787
Access comprehensive clinical trial information for NCT06312787 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Recruitment Completed. The study focuses on Cystic Fibrosis. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vertex Pharmaceuticals Incorporated
Timeline & Enrollment
Phase 1
Apr 02, 2024
May 01, 2024
Primary Outcome
Maximum Observed Plasma Concentration (Cmax) of VX-118,Area Under the Concentration Versus Time Curve (AUC) of VX-118
Summary
The purpose of this study is to evaluate the relative bioavailability, effect of food on the
 pharmacokinetic parameters, and safety and tolerability, of a tablet formulation of VX-118 in
 healthy participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06312787
Non-Device Trial